Evidence map›Paper›PMID 41035136›Full record

ArticleBritish journal of haematology2025

Prognostic significance of pretransplant

Minseung Suh, Jaewon Hyung, Chan-Sik Park, Heounjeong Go, In Hye Song, Eun Jin Chae, Kyung Won Kim, Yoon Sei Lee, Minsu Kwon, Sang-Wook Lee and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Prognostic significance of pretransplantBritish journal of haematology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Minseung SuhDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0009-0008-8502-5341
Jaewon HyungDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Chan-Sik ParkDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-9783-4498
Heounjeong GoDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
In Hye SongDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Eun Jin ChaeDepartment of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kyung Won KimDepartment of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Yoon Sei LeeDepartment of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Minsu KwonDepartment of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Sang-Wook LeeDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-6640-8349
Jiwon LeeDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Shin KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kyoungmin LeeDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Hyungwoo ChoDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Jin-Sook RyuDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-8289-3548

Funding

Asan Institute for Life Sciences 2021IP0031NCIRD CDC HHS U01 IP000031
6 · The paper itself

Abstract

Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients with partial response (PR) to salvage chemotherapy show heterogeneous outcomes after autologous stem cell transplantation (ASCT). Current visual positron emission tomography (PET) assessment inadequately identifies patients likely to benefit from transplantation. We retrospectively evaluated the prognostic value of semiquantitative metrics from interim

Indexed as

Fluorodeoxyglucose F18Hematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffusePositron Emission Tomography Computed TomographySalvage TherapyAdultAgedFemaleHumansMaleMiddle AgedPrognosisRecurrenceRetrospective StudiesTransplantation, AutologousFluorodeoxyglucose F1818F‐FDG PET/CTDeauville 5‐point scalediffuse large B‐cell lymphomaprognostic biomarkersemiquantitative analysistumour‐to‐liver SUV ratio

Identifiers

PMID41035136
PMCPMC12710163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.